News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytRx Corporation (CYTR) Reports 2013 First Quarter Financial Results


5/9/2013 7:54:15 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 31, 2013.

“We are focusing on advancing the clinical development of aldoxorubicin for the treatment of patients with soft tissue sarcoma as well as for various other indications, and expanding our oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents,” said Steven A. Kriegsman, CytRx President and CEO.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES